The Lancet. Rheumatology. 2020 Aug;2(8):e457-ee458. doi: 10.1016/S2665-9913(20)30167-3 Q115.02024

Canakinumab in a subgroup of patients with COVID-19

卡那奴单抗在COVID-19患者亚组中的应用翻译改进

Claudio Ucciferri^{1 2}, Antonio Auricchio¹, Marta Di Nicola³, Nicola Potere⁴, Antonio Abbate⁴, Francesco Cipollone⁵, Jacopo Vecchiet¹, Katia Falasca¹

作者单位 +展开

作者单位

¹ Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. d'Annunzio University of Chieti-Pescara, Chieti 66100, Italy.

² Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.

³ Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti 66100, Italy.

⁴ VCU Health Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.

⁵ Clinica Medica Institute, European Center of Excellence on Atherosclerosis, Hypertension and Dyslipidemia, G. d'Annunzio University of Chieti-Pescara, Chieti 66100, Italy.

DOI: 10.1016/S2665-9913(20)30167-3 PMID: 32835251

摘要中英对照阅读

Keywords：COVID-19; Canakinumab

关键词：新冠; 卡那奴单抗

相关内容

期刊名：Lancet rheumatology

缩写：

ISSN：2665-9913

e-ISSN：

IF/分区：15.0/Q1

文章目录更多期刊信息

全文链接

官方链接

PMC全文

引文链接

复制

已复制！

格式：

Canakinumab in a subgroup of patients with COVID-19

卡那奴单抗在COVID-19患者亚组中的应用翻译改进

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

案例报告：卡那奴单抗用于治疗COVID-19急性呼吸窘迫综合征患者

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis

卡那奴单抗和瑞德西韦在中重度COVID-19患者中的应用：回顾性分析

Efficacy of canakinumab in mild or severe COVID-19 pneumonia

卡那奴单抗治疗轻型或重型新冠肺炎肺炎的疗效研究

Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders

卡那奴单抗可能有助于防止自身炎症性疾病的患者出现严重COVID-19症状

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab

冠状病毒疾病2019(COVID-19)引起的心肌细胞功能障碍、心律失常及卡那奴单抗的影响

Blockage of interleukin-1β with canakinumab in patients with Covid-19

新冠肺炎患者的白细胞介素-1β卡那珠单抗阻断疗法

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial

卡那奴单抗对重症新冠肺炎患者的生存试验证实无需有创机械通气：一项随机临床试验

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

卡那奴单抗早期用药预防部分新冠肺炎患者插管：一项回顾性观察分析

Canakinumab in a subgroup of patients with COVID-19

卡那奴单抗在COVID-19患者亚组中的应用 翻译改进

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

案例报告：卡那奴单抗用于治疗COVID-19急性呼吸窘迫综合征患者

Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis

卡那奴单抗和瑞德西韦在中重度COVID-19患者中的应用：回顾性分析

Efficacy of canakinumab in mild or severe COVID-19 pneumonia

卡那奴单抗治疗轻型或重型新冠肺炎肺炎的疗效研究

Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders

卡那奴单抗可能有助于防止自身炎症性疾病的患者出现严重COVID-19症状

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab

冠状病毒疾病2019(COVID-19)引起的心肌细胞功能障碍、心律失常及卡那奴单抗的影响

Blockage of interleukin-1β with canakinumab in patients with Covid-19

新冠肺炎患者的白细胞介素-1β卡那珠单抗阻断疗法

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial

卡那奴单抗对重症新冠肺炎患者的生存试验证实无需有创机械通气：一项随机临床试验

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

卡那奴单抗早期用药预防部分新冠肺炎患者插管：一项回顾性观察分析

卡那奴单抗在COVID-19患者亚组中的应用翻译改进